睿知中国疾病研究地图
候选清单0

福州福建医科大学

福建医科大学孟超肝胆医院

Mengchao Hepatobiliary Hospital of Fujian Medical University

在本站收录的 53 种疾病中,这家医院列在其中 2 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

福建医科大学孟超肝胆医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 肝细胞癌Hepatocellular carcinoma84 篇牵头论文牵头 3 项开放试验
  2. 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文

未列出的收录疾病:鼻咽癌、食管鳞状细胞癌、胃癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、骨肉瘤、胃肠道间质瘤、神经母细胞瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 84 篇,占 0.6%。

牵头论文
84
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
11
由其他机构牵头
每年牵头的论文数
2021: 131320212022: 141420222023: 191920232024: 161620242025: 22222025

福州有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 14

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
    分期
    II期
    开始
    2024-03
    登记号
    NCT06280105

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学孟超肝胆医院福州

  2. 正在招募
    Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
    分期
    II期
    开始
    2024-04
    登记号
    NCT06349317

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学孟超肝胆医院福州

  3. 正在招募
    A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
    分期
    未注明
    开始
    2022-08
    登记号
    NCT05409482

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学孟超肝胆医院福州

  4. 正在招募
    A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
    分期
    I期
    开始
    2026-04
    登记号
    NCT07478302

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心南宁、福州

  5. 正在招募
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    分期
    I/II期
    开始
    2026-04
    登记号
    NCT07479485

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 7 家列出的医院为研究中心北京、南京、天津、福州、郑州

  6. 正在招募
    A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
    分期
    II期
    开始
    2026-03
    登记号
    NCT07521852

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、福州

  7. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、长春

  8. 正在招募
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    分期
    未注明
    开始
    2025-09
    登记号
    NCT07170345

    年龄 18 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州

  9. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  10. 正在招募
    Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
    分期
    未注明
    开始
    2024-08
    登记号
    NCT06561399

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省立医院;另有 2 家列出的医院为研究中心福州

  11. 正在招募
    Neoadjuvant Triple Therapy for Resectable HCC
    分期
    未注明
    开始
    2024-09
    登记号
    NCT06569498

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省立医院;另有 4 家列出的医院为研究中心厦门、福州

  12. 正在招募
    Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
    分期
    未注明
    开始
    2024-09
    登记号
    NCT06602011

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建省立医院;另有 4 家列出的医院为研究中心厦门、福州

  13. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  14. 正在招募
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    分期
    I期
    开始
    2023-10
    登记号
    NCT06560827

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、武汉、沈阳、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后手术与肝移植影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科肿瘤内科消化/肝病科
牵头的论文84
  1. Calreticulin Enhances Therapeutic Immune Responses of Dry Thermostat-Stressed Hepatocellular Carcinoma Cell Vaccine.2025ACS nano
  2. Identification of a pyroptosis-related long noncoding RNA signature for determining the prognosis and immune status of hepatocellular carcinoma patients.2025Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  3. Porous platinum nanozyme-amplified capacitance immunoassay for alpha-fetoprotein with hepatocellular carcinoma on an interdigitated gold micro-comb array.2025Analytica chimica acta
  4. Prognostic comparison between LNM and MaVI of hepatocellular carcinoma: a multicenter population-based propensity scores matching study.2025BMC gastroenterology免费全文
  5. Knocking Down SKA1 Inhibits Hepatocellular Carcinoma Progression via Apoptosis: Integrating Single-Cell Transcriptomics With In Vivo and In Vitro Validation.2025BioFactors (Oxford, England)
  6. Mesoporous cerium oxide nanoenzyme for Efficacious impeding tumor and metastasis via Conferring resistance to anoikis.2025Biomaterials
  7. The APP Score: A simple serum biomarker model to enhance prognostic prediction in hepatocellular carcinoma.2025Bioscience trends
  8. RNASEH2C enhances TRAF3IP1 to degrade RAI14 in lysosomes thus hindering macrophage antigen presentation and advancing liver cancer.2025Cell death & disease免费全文
  9. Systemic therapy followed by liver resection improved prognosis of hepatocellular carcinoma associated with macrovascular invasion.2025European journal of medical research免费全文
  10. Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  11. Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study.2025Hepatology international
  12. Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection.2025Hepatology international
  13. Latent class analysis-derived classification for cancer-specific death stratification of hepatocellular carcinoma.2025International journal of cancer
  14. Implantable artificial lymph node enables rapid in vivo neoantigen-specific T-cell generation and expansion for improving antitumor immunity.2025Journal for immunotherapy of cancer免费全文
  15. Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications.2025Journal of experimental & clinical cancer research : CR免费全文
  16. High-Throughput Proteomics Reveals a Novel Small Open Reading Frame-Encoded Peptide That Promotes Hepatocellular Carcinoma Invasion and Migration.2025Journal of proteome research
  17. Construction and validation of a novel model for guiding targeted combined immunotherapy in advanced hepatocellular carcinoma.2025Scientific reports免费全文
  18. Apatinib-Induced STAT1/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma.2025Scientific reports免费全文
  19. Prognostic nutritional index is a better inflammation based prognostic marker in elderly patients with hepatocellular carcinoma after surgery.2025Scientific reports免费全文
  20. Evaluating the efficacy of using large language models in preoperative prediction of microvascular invasion in HCC: a multicenter study.2025Scientific reports免费全文
  21. Impact of metabolic dysfunction-associated fatty liver disease on survival outcomes in patients undergoing radical resection for hepatitis B virus-related hepatocellular carcinoma.2025Scientific reports免费全文
  22. Development and validation of an Immune-related Gene-based model for predicting prognosis and immunotherapy outcomes in hepatocellular carcinoma patients.2025Scientific reports免费全文
  23. Biomimetic Responsive Nanoconverters with Immune Checkpoint Blockade Plus Antiangiogenesis for Advanced Hepatocellular Carcinoma Treatment.2024ACS applied materials & interfaces
  24. Multifunctional Biomimetic Nanocarriers for Dual-Targeted Immuno-Gene Therapy Against Hepatocellular Carcinoma.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  25. Surgical Decision-Making Considerations in Hepatocellular Carcinoma Resection: Safety and Efficacy.2024Annals of surgical oncology
  26. Impact of Hepatic Pedicle Clamping on Long-Term Survival Following Hepatectomy for Hepatocellular Carcinoma: Stratified Analysis Based on Intraoperative Blood Transfusion Status.2024Annals of surgical oncology
  27. The Effect of Microvascular Invasion on Hepatocellular Carcinoma With Portal Vein Tumor Thrombus After Hepatectomy: A Retrospective Study.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  28. RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion.2024Cancer research
  29. Pien Tze Huang Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells by Repressing PDGFRB/YAP/CCN2 Axis Activity.2024Chinese journal of integrative medicine
  30. The prognostic nutritional index as a predictor of efficacy and early recurrence for adjuvant transarterial chemoembolization in hepatocellular carcinoma.2024Clinics and research in hepatology and gastroenterology
  31. TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis.2024EMBO molecular medicine免费全文
  32. Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study.2024Frontiers in immunology免费全文
  33. A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma.2024Hepatology international
  34. Proteomic Analysis Identifies GSN as a Noninvasive Circulating Serum Biomarker for Predicting Early Recurrence of Hepatocellular Carcinoma.2024Journal of proteome research
  35. Nomogram for predicting early recurrence of hepatocellular carcinoma with narrow resection margin.2024Scientific reports免费全文
  36. Safety and efficacy of interventional embolization in cirrhotic patients with refractory hepatic encephalopathy associated with spontaneous portosystemic shunts.2024Scientific reports免费全文
  37. Chalcomoracin promotes apoptosis and endoplasmic reticulum stress in hepatocellular carcinoma cells.2024The Journal of antibiotics
  38. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.2024World journal of surgical oncology免费全文
  39. Development and validation a radiomics nomogram for predicting thymidylate synthase status in hepatocellular carcinoma based on Gd-DTPA contrast enhanced MRI.2023BMC cancer免费全文
  40. Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study.2023British journal of cancer免费全文
  41. Prognostic significance of three-tiered pathological classification for microvascular invasion in patients with combined hepatocellular-cholangiocarcinoma following hepatic resection.2023Cancer medicine免费全文
  42. Prognosis value of microscopic bile duct invasion in hepatocellular carcinoma: A multicenter study.2023Cancer medicine免费全文
  43. Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy.2023Cell reports. Medicine免费全文
  44. Navoximod modulates local HSV-1 replication to reshape tumor immune microenvironment for enhanced immunotherapy via an injectable hydrogel.2023Communications biology免费全文
  45. Prevalence, clinical characteristics, and outcomes of spontaneous portosystemic shunt in patients with hepatitis B-related cirrhosis: A multicenter study from China.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  46. Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression.2023Drug delivery and translational research免费全文
  47. Spleen-targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma.2023EMBO molecular medicine免费全文
  48. Association of primary tumor location with long-term oncological prognosis following hepatectomy for hepatocellular carcinoma:A multicenter propensity score matching analysis.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  49. Analysis of conditional survival in primary hepatocellular carcinoma after narrow-margin hepatectomy: a large-sample, dual-centre, retrospective study.2023HPB : the official journal of the International Hepato Pancreato Biliary Association
  50. Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a r2023Hepatology international
  51. Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propens2023International immunopharmacology
  52. Revolutionising hepatocellular carcinoma surveillance: Harnessing contrast-enhanced ultrasound and serological indicators for postoperative early recurrence prediction.2023Medicine免费全文
  53. Impact of MAFLD on the complications after hepatectomy in patients with HBV-related hepatocellular carcinoma.2023Medicine免费全文
  54. Identification of tumor mutations in plasma based on mutation variant frequency change (MVFC).2023Molecular oncology免费全文
  55. Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma.2023Nature communications免费全文
  56. Normalization of Tumor Vessels by Lenvatinib-Based Metallo-Nanodrugs Alleviates Hypoxia and Enhances Calreticulin-Mediated Immune Responses in Orthotopic HCC and Organoids.2023Small (Weinheim an der Bergstrasse, Germany)
  57. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.2023Theranostics免费全文
  58. Far-Red Light Triggered Production of Bispecific T Cell Engagers (BiTEs) from Engineered Cells for Antitumor Application.2022ACS synthetic biology
  59. Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  60. Efficacy of Adjuvant Transarterial Chemoembolization Combined Antiviral Therapy for HBV-Related HCC with MVI after Hepatic Resection: A Multicenter Study.2022Asian Pacific journal of cancer prevention : APJCP免费全文
  61. Pyroptosis related genes signature predicts prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma.2022BMC cancer免费全文
  62. Immune Analysis and Small Molecule Drug Prediction of Hepatocellular Carcinoma Based on Single Sample Gene Set Enrichment Analysis.2022Cell biochemistry and biophysics
  63. Antiviral Therapy Improves Survival in Hepatocellular Carcinoma with Microvascular Invasion: A Propensity Score Analysis.2022Digestive diseases and sciences
  64. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.2022Frontiers in immunology免费全文
  65. Dysregulation of global circular RNA abundance regulated by spliceosomes predicts prognosis in hepatocellular carcinoma.2022Hepatology communications免费全文
  66. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models.2022Journal for immunotherapy of cancer免费全文
  67. Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data.2022Journal of clinical pharmacology
  68. Copy number profiling of circulating free DNA predicts transarterial chemoembolization response in advanced hepatocellular carcinoma.2022Molecular oncology免费全文
  69. Neoantigen Immunotherapeutic-Gel Combined with TIM-3 Blockade Effectively Restrains Orthotopic Hepatocellular Carcinoma Progression.2022Nano letters
  70. Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study.2022World journal of surgical oncology免费全文
  71. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis.2022World journal of surgical oncology免费全文
  72. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.2021BMC cancer免费全文
  73. A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints.2021Biomaterials science
  74. Accurate transcriptome assembly by Nanopore RNA sequencing reveals novel functional transcripts in hepatocellular carcinoma.2021Cancer science免费全文
  75. Doxifluridine-based pharmacosomes delivering miR-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma.2021Colloids and surfaces. B, Biointerfaces
  76. Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection.2021Digestive diseases and sciences免费全文
  77. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.2021ESMO open免费全文
  78. Quantitative Secretome Analysis Reveals Clinical Values of Carbonic Anhydrase II in Hepatocellular Carcinoma.2021Genomics, proteomics & bioinformatics免费全文
  79. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  80. A remotely controlled NIR-II photothermal-sensitive transgene system for hepatocellular carcinoma synergistic therapy.2021Journal of materials chemistry. B
  81. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.2021Molecular cancer免费全文
  82. Redirecting natural killer cells to potentiate adoptive immunotherapy in solid tumors through stabilized Y-type bispecific aptamer.2021Nanoscale
  83. An MR-based radiomics model for differentiation between hepatocellular carcinoma and focal nodular hyperplasia in non-cirrhotic liver.2021World journal of surgical oncology免费全文
  84. Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study.2021World journal of surgical oncology免费全文
中文论文(未计入)3
  1. [Comparison of the efficacy of anatomical resection versus hepatic parenchymal preservation preference in patients with solitary small hepatocellular carcinoma and cirrhosis: a multicenter retrospective study].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Safety and efficacy of TIPS combined with iodine-125 seed strands in the treatment of patients with hepatocellular carcinoma combined with portal vein tumor thrombosis].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)26
  1. A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib正在招募NCT06280105牵头方II期2024-03 启动
  2. A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma正在招募NCT05409482牵头方2022-08 启动
  3. Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT正在招募NCT06349317牵头方(推断)II期2024-04 启动
  4. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  5. A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma正在招募NCT07478302研究中心I期2026-04 启动
  6. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)正在招募NCT07479485研究中心I/II期2026-04 启动
  7. A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC正在招募NCT07521852研究中心II期2026-03 启动
  8. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion正在招募NCT07170345研究中心2025-09 启动
  9. Neoadjuvant Triple Therapy for Resectable HCC正在招募NCT06569498研究中心2024-09 启动
  10. Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)正在招募NCT06561399研究中心2024-08 启动
  11. Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)正在招募NCT06602011研究中心2024-09 启动
  12. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  13. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  14. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection正在招募NCT06560827研究中心I期2023-10 启动
  15. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  16. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)已终止NCT06487559研究中心I期2024-09 启动
  17. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)进行中,不再招募NCT05904886研究中心III期2023-09 启动
  18. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma已终止NCT05653427研究中心II期2022-12 启动
  19. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  20. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  21. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  22. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  23. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  24. Prospective Surveillance for Very Early Hepatocellular Carcinoma状态不明NCT03588442研究中心2018-07 启动
  25. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)已完成NCT02112656研究中心III期2014-06 启动
  26. Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression状态不明NCT01681446研究中心III期2012-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头

福州有 4 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

福建医科大学孟超肝胆医院

Mengchao Hepatobiliary Hospital of Fujian Medical University

福州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Mengchao Hepatobiliary Hospital; Mengchao hepatobiliary Hospital of Fujian Medical University; Mengchao Hepatobiliary Hospital of Fujian. Medical University; Mengchao Hepatobiliary Surgery Hospital; United Innovation of Mengchao Hepatobiliary Technology; First Affiliated and Mengchao Hepatobiliary Surgery Hospital

提出更正下载数据